Actinium Index

Cancer

- Hematopoietic Stem
  Cell Transplantation

Two drug candidates to treat blood borne cancers have been tested in approximately 300 patients in Phase I and II clinical trials
Actimab-A is in a Phase I/II clinical trial in patients with Acute Myeloid Leukemia or AML who are over the age of 60
Iomab™-B will begin a pivotal trial for preparing bone marrow of patients with certain blood cancers before they receive a hematopoietic stem cell transplant or HCST
Technology platform couples monoclonal antibodies with extremely potent but comparatively safe radioactive isotopes, in particular the alpha-emitter Actinium 225
Robust pre-clinical pipeline that the company intends to progress into clinical trials in the next twelve to eighteen months